Will he be saying anything about Anavex’s small molecules as treatments for Alzheimer’s? If he doesn’t it will reveal that he’s ignorant of Anavex science and that he’s not presenting a wide, inclusive description of new Alzheimer’s therapies.
Most probably he will mention Anavex. But what will he say? “And there’s Anavex, with their new drug candidate blarcamesine. It’s still in clinical trials.”
Or, will he be more definitive in the status of the Anavex drug? Someone will have to report to us what he says.